Breakthrough drug tested for patients who failed all other treatments
NCT ID NCT06764160
Summary
This study tested whether the drug eculizumab could help control severe myasthenia gravis in Chinese patients whose disease didn't respond to other treatments. Fifteen participants with significant muscle weakness received the drug for 26 weeks while researchers measured improvements in daily activities and quality of life. The goal was to see if this already-approved medication could provide better disease control for this difficult-to-treat population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Changchun, 130021, China
-
Research Site
Fuzhou, 350001, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Guangzhou, 510620, China
-
Research Site
Qingdao, 266035, China
-
Research Site
Shanghai, 200040, China
Conditions
Explore the condition pages connected to this study.